Choosing an HLA typing platform is easier when you treat it as a project-scoping problem, not a technology debate. In the sections below, you'll see how short-read NGS, Sanger sequencing, and long-read approaches differ in practical terms—resolution, ambiguity risk, phasing confidence, batch scalability, and reporting needs—plus when a combined workflow is the most defensible strategy for research teams.

Key Takeaways for Choosing an HLA Typing Platform

• NGS is often the best starting point for multi-locus, high-resolution, or batch HLA typing projects.
• Sanger sequencing remains useful for targeted confirmation or small, focused questions.
• Long-read sequencing adds value when phasing, full-length context, or complex allele resolution is central to the project.
• Ambiguous HLA calls should be anticipated before the study starts, especially for key samples.
• Platform choice should consider sample number, target loci, resolution, data deliverables, and downstream research use.
• A combined workflow can be more practical than forcing every project into a single platform.

Why Platform Choice Matters in HLA Typing Projects

HLA typing platform choice affects more than "what sequencer you use." It shapes what resolution you can support, how often you'll face ambiguous allele combinations, and whether you can defend phasing confidence when the project scales from a pilot to recurring batches.

The real decision is not "which technology is best?"

No single platform fits every HLA typing project. The decision should follow project variables such as:

• Target loci
• Required resolution (is 2-field enough, or do you need allele-level detail?)
• Sample count and batch structure
• Sample quality and replaceability
• Ambiguity risk
• Downstream research use
• Whether phasing or full-length context is needed

This article compares short-read NGS, Sanger sequencing, and long-read sequencing for research project decision-making.

A quick answer for busy project teams

• Choose NGS when you need scalable, high-resolution HLA typing for multiple loci or multiple samples.
• Choose Sanger when you need targeted confirmation or a smaller, focused typing question.
• Choose long-read sequencing when phasing, full-length gene context, or complex allele resolution is central to the project.
• Use a combined strategy when a key sample has ambiguity or when results must be highly traceable for downstream research.

If you expect high ambiguity risk, plan for HLA typing ambiguity resolution before the study starts by defining an escalation path for key samples.

Start With the Research Question, Not the Platform

The right HLA typing method should be selected after the team defines what decision the result needs to support. That's what keeps you from overspending on "maximum" methods for low-value samples, or under-testing the one sample that drives the next experiment.

Are you annotating samples or resolving a critical HLA question?

Two patterns show up repeatedly in real projects.

Routine sample annotation: you need consistent, multi-locus calls across a batch, with a report format that stays comparable over time.

High-value decision support: one sample is the bottleneck (an engineered cell line, a rare-disease cohort outlier, an irreplaceable reference material). If that sample yields an ambiguous call, you need an escalation path built into the plan.

What will HLA typing results be used for?

Keep the use cases research-oriented and decision-linked:

• Cohort characterization and sample stratification
• Donor or cell line comparison
• Multi-omics immunogenetics metadata alignment
• Gene editing support (documenting allele background before allele-specific edits)
• Rare allele investigation and long-term reference sample documentation

A simple pre-selection checklist

• Which loci are required?
• Is 2-field enough, or is allele-level resolution needed?
• How many samples are included (and will this repeat across batches)?
• Are samples limited, degraded, or irreplaceable?
• Is phase information important?
• Are rare or novel alleles expected?
• Will results be integrated with other omics data?
• Is confirmation needed for key samples?

When NGS HLA Typing Is Usually the Best Starting Point

NGS is often the most practical starting platform when a research team needs high-resolution HLA typing across multiple loci, multiple samples, or repeatable project batches.

Strengths of NGS for HLA typing

Short-read NGS tends to work well when you need:

• Multi-locus HLA coverage in a single project
• Standardization across batches
• A clear path from raw data to a report that can be re-used and re-analyzed later

It also fits the typical "decision-stage" requirement: produce a high-confidence baseline result for the cohort, then escalate only the specific samples that need more context.

Where NGS fits best in research projects

NGS is a strong default for:

• Medium-to-large sample batches
• Cohort/population research
• Routine characterization of donor material or cell lines
• Multi-omics projects where metadata consistency matters

What NGS may not fully resolve

Short-read NGS can still struggle when the limiting factor is long-distance phasing or full-length locus context. In other words: even when you see the variants, you may not be able to confidently connect them into a single phased allele across the full locus (for a discussion of standardized reporting challenges and phasing limits, see Challenges for the Standardized Reporting of NGS HLA Genotyping).

That's the point where "more coverage" may not be the answer, and a different read-length strategy becomes more rational.

When Sanger HLA Typing Still Makes Sense

Sanger sequencing can still be useful when the project question is narrow, targeted, or confirmation-oriented rather than broad and multiplexed.

Strengths of Sanger in focused questions

Use Sanger when you need Sanger HLA typing confirmation for a specific locus or region, especially as a follow-up to clarify uncertainty on a key sample.

This is also where Sanger's strengths show clearly: well-understood workflows, targeted scope, and high per-read accuracy for the region you sequence.

Limitations that matter for HLA projects

A recurring limitation of traditional exon-focused typing is that it can hinder assignment of higher-resolution genotypes when variation outside the targeted region matters, or when phasing cannot be confidently established in complex heterozygous contexts. A 2024 review summarizes how these constraints drove adoption of broader sequencing approaches in high-resolution HLA typing workflows (see Advancements in HLA typing techniques and their impact (2024)).

In practical project terms, these limitations show up as:

• More ambiguous allele combinations to reconcile
• More follow-up testing for key samples
• A weaker path to full-length context when that context is part of the research question

Best use case: confirmation, not always first-line discovery

If your scope is "type a cohort across multiple loci," Sanger is rarely the most efficient first-line approach.

If your scope is "confirm this one critical call because it changes the next experiment," Sanger can be a sensible tool inside a combined workflow.

When Long-Read HLA Typing Adds Real Value

Long-read HLA typing becomes valuable when the research question depends on phasing, full-length context, or resolving complex allele structures that shorter reads may not fully clarify.

Why read length matters in HLA typing

Long reads can span larger regions, which changes what you can phase directly.

For decision-stage teams, the key point isn't "long-read is newer." It's this: if your ambiguity is driven by lack of phase or missing long-range context, longer reads are often the most direct way to reduce that uncertainty.

A 2026 peer-reviewed framework focusing on long-read typing of polymorphic immune genes reports high-resolution HLA typing performance and emphasizes reconstructing personalized haplotypes across HLA loci from long-read data (see A scalable framework for comprehensive typing of polymorphic immune genes including HLA (2026)).

Research scenarios that justify long-read sequencing

Long-read sequencing is usually justified when at least one of the following is true:

• Your primary NGS result produces unresolved ambiguity that blocks downstream work
• The project requires long-read HLA typing phasing (not just allele calls)
• Full-length HLA locus context is a deliverable (reference materials, long-term documentation)
• Rare or novel alleles are plausible and you need an evidence trail for interpretation

When long-read may be more than the project needs

For routine batch typing and standard cohort annotation, NGS is often more practical.

A common best-fit pattern is selective long-read sequencing for only the samples where phasing/full-length context materially affects downstream research.

How to Compare Platforms by Project Variables

Method & reporting notes (for research workflows)

To make HLA typing results reusable and comparable across batches, ask your provider to document:

• The reference database used (e.g., IPD-IMGT/HLA) and the database release/version reported with each batch
• Locus and region coverage assumptions (exon-only vs extended regions) and the intended reporting resolution
• How ambiguous calls are labeled and what triggers an escalation step (repeat, targeted confirmation, or long-read sequencing)
• The deliverables you will receive (per-sample allele calls, ambiguity flags/notes, and summary tables for downstream analysis)

Compare platforms by variables you can put into a scope statement.

Variable 1 — Sample number and batch structure

• Small, narrow questions: a targeted approach can be reasonable.
• Medium-to-large batches: NGS usually fits better.
• Few samples but high consequence: long-read or combined strategies can be justified.

Variable 2 — Required resolution

2-field may be enough for basic research annotation.

Higher-resolution typing tends to matter more when your downstream analysis is allele-specific, when you're comparing closely related cell lines, or when you're creating reference materials where re-analysis and traceability matter.

Variable 3 — Ambiguity risk

Ambiguity is not random. Risk increases with factors like heterozygosity, homologous sequences, rare alleles, incomplete coverage, limited read length, and complex locus structure (for a recent set of recommendations on HLA genotyping data practices and reporting expectations, see: https://pmc.ncbi.nlm.nih.gov/articles/PMC13094400/).

If you expect higher ambiguity risk, treat it as a study design input and define the escalation path upfront.

Variable 4 — Phasing and full-length context

If you only need sample-level annotation, phasing may not be central.

If you need allele-level interpretation that depends on long-range connections, phasing and full-length context become decision-critical, and long-read sequencing becomes more relevant.

Variable 5 — Data integration needs

Platform choice is also a data-usability decision.

If HLA typing results will be integrated with other assays, consistent metadata and file deliverables become part of the platform decision (see BCR and TCR Sequencing and Single Cell RNA Sequencing).

A Practical Decision Table for Choosing an HLA Typing Platform

How to use this table without oversimplifying

This table is a starting point. The final choice still depends on sample condition, loci list, and downstream use.

What Competitor Pages Often Miss About Platform Choice

Many technology pages explain what their method can do. Project teams also need to know when a platform is best used in combination.

Technology claims need project context

"High resolution" and "phased results" are not decision criteria on their own.

Decision criteria are contextual: loci, resolution target, ambiguity tolerance, downstream decision, and the evidence trail you'll need in the report.

A combined strategy is sometimes the most rational choice

A combined workflow often balances scale and certainty:

• NGS HLA typing for the cohort baseline
• Sanger HLA typing confirmation when a specific region needs targeted validation
• Long-read sequencing when phasing/full-length context is the limiting factor

The report must be useful beyond the typing result

A strong report supports re-analysis, comparison across batches, and downstream integration. It should also document reference context and versions.

Example Scenarios: How Different Teams Might Choose

Scenario 1 — A CRO needs to type 120 research samples across multiple loci

Recommendation logic: use NGS as the primary platform for throughput, multi-locus coverage, and standardized reporting. Define in advance how ambiguous calls will be handled for the small subset of samples that drive downstream decisions.

Scenario 2 — A biotech team has one critical engineered cell line with an ambiguous call

Recommendation logic: review the NGS evidence first, then escalate based on what drives the ambiguity. If the uncertainty is about long-range phase/full-length context, long-read is often the cleaner path.

If the HLA background is part of an allele-specific editing program, align the validation plan with adjacent workflows such as CRISPR Validation Sequencing.

Scenario 3 — An immunogenetics group is investigating rare alleles in a diverse cohort

Recommendation logic: NGS for scale, long-read for selected unresolved samples. This keeps the study defensible without turning every sample into a maximal-complexity case.

Scenario 4 — A team needs full-length HLA context for reference cell materials

Recommendation logic: long-read sequencing (or a combined strategy where long-read is the resolution step) because the long-term value is in phased, full-length context.

What to Ask an HLA Typing Service Provider Before Choosing a Platform

Ask questions that reveal whether the provider understands loci coverage, resolution, ambiguity handling, and reporting.

Questions about loci and resolution

• Which HLA loci can be covered?
• What resolution can be reported for each locus?
• Can class I and class II loci be included in the same project?
• How are 2-field and higher-resolution results defined in the report?

Questions about ambiguity and confirmation

• How are ambiguous calls flagged?
• What happens if multiple allele combinations remain plausible?
• Can Sanger confirmation be added for targeted regions?
• Can long-read sequencing be used for unresolved phasing questions?
• How is confidence communicated?

Questions about data deliverables

• Will the report include allele calls by locus?
• Is the reference database version documented?
• Are sample-level summary tables provided?
• Can results be organized for downstream multi-omics analysis?

Questions about project fit

• What platform is recommended for my sample number and target loci?
• Is my project better suited for primary typing or a combined workflow?
• Are any samples likely to require additional confirmation?

How CD Genomics Helps Research Teams Select an HLA Typing Strategy

CD Genomics can support research-use HLA typing projects by helping teams match target loci, resolution requirements, sample scale, and ambiguity risk with an appropriate sequencing strategy (services are intended for Research Use Only).

For related service context, see Biomedical NGS Platform and the HLA Typing Sequencing service page.

Fit-for-purpose platform guidance

A fit-for-purpose recommendation should make the trade-offs explicit, define an escalation path for ambiguity/phasing, and set clear reporting expectations.

When to consider a combined workflow

A combined workflow is often justified when a key sample needs higher confidence, when rare alleles are expected, or when cohort-scale typing leaves decision-blocking ambiguity.

Mini case examples (anonymized)

What a decision-ready research report should include

At minimum, make sure the report records:

• Allele calls by locus and reported resolution (e.g., 2-field vs higher)
• An ambiguity flag/notes field (what is ambiguous and why)
• Evidence notes for escalation (e.g., "phasing uncertainty" vs "region-specific conflict")
• Reference database and release/version used for the call
• Deliverables for downstream reuse (per-sample tables + batch summary)

FAQ

Is NGS better than Sanger for HLA typing?

NGS is usually better suited for multi-locus, higher-throughput HLA typing projects because it can scale across samples and loci while producing standardized outputs for cohort-level analysis. Sanger can still be the right tool when the question is narrow and confirmation-focused, especially when you need to validate a specific region for a key sample rather than build a full typing program.

When should I use long-read HLA typing?

Long-read HLA typing is most useful when the project requires phasing, full-length gene context, investigation of rare or difficult alleles, or resolution of ambiguous calls that remain unresolved after a primary workflow. It is often most defensible as a targeted strategy for the subset of samples where long-range information changes the downstream decision.

Can Sanger resolve HLA ambiguity?

Sanger may help confirm targeted regions, but ambiguity driven by phase uncertainty or complex heterozygosity may persist. In those cases, a combined approach with long-range phasing support is more likely to produce a decision-ready result.

Is 2-field HLA typing enough for research projects?

2-field typing may be enough for basic sample annotation and cohort characterization when allele-level differences do not drive downstream decisions. Higher resolution matters more for allele-specific work or highly traceable reference materials.

Can one HLA typing project use more than one platform?

Yes. A practical strategy often uses NGS as the cohort baseline, then adds targeted confirmation or long-read sequencing for the specific samples where ambiguity, phasing, or full-length context materially affects downstream research.

Further reading

For additional related content, visit the Learning Center. For background on HLA reference database versioning, see the IPD-IMGT/HLA release documentation and the Nucleic Acids Research update on recent developments (2025/2026).